Summit Therapeutics Inc. (SMMT) has pivoted its clinical focus to a Phase 2 trial evaluating ivonescimab in patients with non-small cell lung cancer (NSCLC), signaling strategic refinement in its oncology pipeline. The trial aims to enroll approximately 140 patients across multiple U.S. sites.
- Phase 2 trial of ivonescimab targeting 140 NSCLC patients with PD-L1 positive tumors
- Primary endpoint: objective response rate per RECIST 1.1; secondary endpoints include PFS and DoR
- NSCLC accounts for ~85% of lung cancer cases, with over 230,000 U.S. diagnoses annually
- SMMT stock rose 12% pre-market; XLV and IEX also registered gains
- Trial results expected by late 2027; funding from $120M cash reserve as of Q4 2025
- Potential for accelerated approval if early efficacy signals are strong
Summit Therapeutics Inc. (SMMT) has announced a targeted clinical advancement with the initiation of a Phase 2 trial evaluating ivonescimab, a monoclonal antibody designed to modulate immune checkpoint pathways, in patients with advanced non-small cell lung cancer (NSCLC). The trial will enroll approximately 140 participants with PD-L1 positive tumors who have progressed on prior therapy, including platinum-based chemotherapy and immune checkpoint inhibitors. The primary endpoint is objective response rate as assessed by RECIST 1.1 criteria, with secondary endpoints including progression-free survival and duration of response. The decision to prioritize NSCLC reflects a strategic shift toward high-impact oncology indications where unmet medical need remains substantial. According to company disclosures, NSCLC accounts for roughly 85% of all lung cancer cases, with over 230,000 new diagnoses annually in the United States alone. Ivonescimab’s mechanism—targeting the LAG-3 pathway—positions it as a potential combination therapy candidate with existing PD-1 inhibitors, a class that includes drugs from companies such as Bristol Myers Squibb and Merck. SMMT’s stock (SMMT) has seen a 12% increase in pre-market trading following the announcement, indicating investor optimism around the potential for a differentiated immune therapy. The biotech’s share price moves are also being mirrored in broader healthcare ETFs such as XLV, which rose 0.8% in early trading, while IEX, a biotech-focused index, gained 1.3%. Analysts note that while the trial is not expected to report results before late 2027, the trial’s design and patient population align with regulatory pathways for accelerated approval if early signals are favorable. The trial’s execution will be overseen by Summit Therapeutics’ clinical development team in collaboration with academic medical centers in the U.S., including the University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering. Funding for the study is being covered through ongoing operations and a portion of the company’s $120 million cash reserve as of Q4 2025.